

Multiple Sclerosis (MS) Relapsing Multiple Sclerosis (RMS)

Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

Trial Status
Active, not recruiting

Trial Runs In
3 Countries

Trial Identifier
NCT04377555 ML42071

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.

Genentech, Inc.
Sponsor

Phase 4
Phase

NCT04377555 ML42071
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 65 Years

Healthy Volunteers
No